CDKN2A Forward PCR Primer (200bp position)
- Known as:
- CDKN2A Forward PCR test kit Primer (200bp position)
- Catalog number:
- MP1123
- Product Quantity:
- ea
- Category:
- -
- Supplier:
- Panomics
- Gene target:
- CDKN2A Forward PCR Primer (200bp position)
Related genes to: CDKN2A Forward PCR Primer (200bp position)
- Gene:
- CDKN2A NIH gene
- Name:
- cyclin dependent kinase inhibitor 2A
- Previous symbol:
- CDKN2, MLM
- Synonyms:
- CDK4I, p16, INK4a, MTS1, CMM2, ARF, p19, p14, INK4, p16INK4a, p19Arf, p14ARF
- Chromosome:
- 9p21.3
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-19
- Date modifiied:
- 2019-04-23
- Gene:
- CDKN2A-DT NIH gene
- Name:
- CDKN2A divergent transcript
- Previous symbol:
- C9orf53, CDKN2A-AS1
- Synonyms:
- bA149I2.3
- Chromosome:
- 9p21.3
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2004-07-23
- Date modifiied:
- 2018-03-22
Related products to: CDKN2A Forward PCR Primer (200bp position)
Related articles to: CDKN2A Forward PCR Primer (200bp position)
- is a long non-coding RNA (lncRNA) located on chromosome 9 that plays a critical regulatory role in various malignancies, including ovarian cancer and lung cancer. However, its involvement in oral squamous cell carcinoma (OSCC) and the underlying molecular mechanisms remain poorly characterized. This study aims to investigate the expression profile, functional roles, and molecular mechanisms of lncRNA in OSCC. - Source: PubMed
Publication date: 2026/04/24
Liao KeLv WeiFeng BinghuaSu XiaopingHuang Xuanping - Necroptosis is a caspase-independent regulated necrotic cell death modality that elicits strong adaptive immune responses, and has the potential to activate antitumor immunity. Long non-coding RNAs (lncRNAs) have critical effects on oral squamous cell carcinoma (OSCC), which are closely associated with the prognosis and immune regulation of OSCC patients. - Source: PubMed
Ji LantingLiang ShuangCheng YahsinGao RuifangYan WenpengPang FangZhang Fang - The novel form of regulatory cell death, cuproptosis, is characterized by proteotoxicity, which ultimately leads to cell death. Its targeting has emerged as a promising therapeutic approach for oral squamous cell carcinoma (OSCC). Long noncoding RNAs (lncRNAs) participate in epigenetic regulation and have been linked to the progression, prognosis, and treatment of OSCC. Thus, this study aimed to identify new cuproptosis-related lncRNAs (CRLs), establish predictive models for clinical prognosis, immune response, and drug sensitivity, and provide novel insights into immune escape and tumor drug resistance. - Source: PubMed
Publication date: 2024/02/27
Liang ShuangJi LantingYu ZhenyuanCheng YaHsinGao RuifangYan WenpengZhang Fang - Lung adenocarcinoma is a common cause of mortality in patients with cancer. Recent studies have indicated that copper-related cell death may not occur in the same way as previously described. Long non-coding RNAs (lncRNAs) play a key role in the occurrence and development of tumors; however, the relationship between cuproptosis and lncRNAs in tumorigenesis and lung adenocarcinoma (LUAD) treatment has not been well established. Our study aimed to construct a model to analyze the prognosis of lung adenocarcinoma in patients using a carcinogenesis-related lncRNA (CR) signature. The transcriptional profiles of 507 samples from The Cancer Genome Atlas were assessed. Cox regression and co-expression analyses, and the least absolute shrinkage and selection operator (LASSO) were used to filter the CR and develop the model. The expression status of the six prognostic CRs was used to classify all samples into high- and low-risk groups. The overall disease-free survival rate was compared between the two groups. The Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes were used to identify the pathways and mechanisms involved in this model. Subsequently, immunotherapy response, sensitivity, and correlation analyses for several anti-tumor medications were performed. experiments, including qPCR, were conducted in nine lung adenocarcinoma cell lines and 16 pairs of lung adenocarcinoma and para-carcinoma tissues. After confirmation using the ROC curve, patients in the low-risk category benefited from both overall and disease-free survival. Gene Ontology analysis highlighted cell movement in the model. In the experiments, qPCR results showed the expression levels of six CRs in 16 pairs of carcinoma and para-carcinoma tissues, which were in accordance with the results of the model. AL138778.1 is a protective factor that can weaken the invasion and migration of A549 cells, and AL360270.1 is a hazardous factor that promotes the invasion and migration of A549 cells. According to this model, targeted treatments such as axitinib, gefitinib, linsitinib, pazopanib, and sorafenib may be more appropriate for low-risk patients. Six CR profiles (AL360270.1, AL138778.1, CDKN2A-DT, AP003778.1, LINC02718, and AC034102.8) with predictive values may be used to evaluate the prognosis of patients with lung adenocarcinoma undergoing therapy. - Source: PubMed
Publication date: 2023/09/07
Zhang MengzheXiao ZengtuanXie YongjieLi ZekunZhang LianminZhang Zhenfa - The incidence of head and neck squamous cell carcinoma (HNSCC), one of the most prevalent tumors, is increasing rapidly worldwide. Cuproptosis, as a new copper-dependent cell death form, was proposed recently. However, the prognosis value and immune effects of cuproptosis-related lncRNAs (CRLs) have not yet been elucidated in HNSCC. - Source: PubMed
Publication date: 2023/07/19
Zheng XiwangZheng DefeiZhang ChunmingGuo HuinaZhang YuliangXue XutingShi ZhaohuiZhang XiangminZeng XianhaiWu YongyanGao Wei